Hans Gelderblom, MD, PhD, discusses the correlation between the overall response rate by Tumor Volume Score and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
Hans Gelderblom, MD, PhD, professor of medical oncology at Leiden University Medical Centre, discusses the correlation between the overall response rate by Tumor Volume Score (TVS) and RECIST 1.1 criteria in patients with advanced tenosynovial giant cell tumors treated with pexidartinib.
In the phase III ENLIVEN trial, there was a 39% response rate by RECIST criteria in patients randomized to pexidartinib. However, these patients also had a 56% response rate by TVS criteria, says Gelderblom.
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More